Cingulate Inc. Files 8-K Report

TL;DR

Cingulate Inc. filed an 8-K on Aug 15th covering other events and financials.

AI Summary

On August 15, 2024, Cingulate Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware with its principal executive offices in Kansas City, KS, operates in the Pharmaceutical Preparations industry.

Why It Matters

This filing provides an update on Cingulate Inc.'s corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of events and financial statements, not indicating any immediate significant operational or financial changes.

Key Numbers

• 001-40874 — SEC File Number (Identifies the company's filing with the SEC.)
• 86-3825535 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Cingulate Inc. (company) — Registrant
• August 15, 2024 (date) — Date of earliest event reported
• Kansas City, KS (location) — Principal executive offices
• Delaware (location) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share CING The Nasdaq Stock Mar
• $8,470,000 — ight & Co., dated January 3, 2023, from $8,470,000 to $11,326,658 and filed a prospectus s
• $11,326,658 — ted January 3, 2023, from $8,470,000 to $11,326,658 and filed a prospectus supplement (the
• $2,856,658 — the Sales Agreement for an aggregate of $2,856,658. Prior to the date hereof, the Company
• $8,468,402.99 — tock having an aggregate sales price of $8,468,402.99 under the Sales Agreement. A copy of th

Filing Documents

• form8-k.htm (8-K) — 44KB
• ex5-1.htm (EX-5.1) — 12KB
• ex5-1_001.jpg (GRAPHIC) — 4KB
• ex5-1_002.jpg (GRAPHIC) — 4KB
• 0001493152-24-032926.txt ( ) — 283KB
• cing-20240815.xsd (EX-101.SCH) — 4KB
• cing-20240815_def.xml (EX-101.DEF) — 26KB
• cing-20240815_lab.xml (EX-101.LAB) — 36KB
• cing-20240815_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 6KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 CINGULATE INC. (Exact name of registrant as specified in its charter) Delaware 001-40874 86-3825535 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 1901 W. 47th Place Kansas (Address of principal executive offices) (Zip Code) (913) 942-2300 (Registrant's telephone number, including area code) (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of exchange on which registered Common Stock, par value $0.0001 per share CING The Nasdaq Stock Market LLC (Nasdaq Capital Market) Warrants, exercisable for one share of common stock CINGW The Nasdaq Stock Market LLC (Nasdaq Capital Market) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Events. On August 19, 2024, Cingulate Inc. (the "Company") increased the maximum aggregate offering price of the shares of the Company's common stock, par value $0.0001 per share (the "Common Stock") issuable under the At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., dated January 3, 2023, from $8,470,000 to $11,326,658 and filed a prospectus supplement (the "Current Prospectus Supplement") under the Sales Agreement for an aggregate of $2,856,658. Prior to the date hereof, the Company sold shares of common stock having an aggregate sales price of $8,468,402.99 under the Sales Agreement. A copy of the legal opinion as to the legality of the $2,856,658 of shares of Common Stock issuable under the Sales Agreement and covered by the Current Prospectus Supplement is filed as Exhibit 5.1 attached hereto. On August 15, 2024, the Company announced that it was issued a European patent for its lead asset CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The patent application was granted on August 14, 2024, as EP Patent No. 3261625, and will include up to 30 European territories, including the United Kingdom. Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Lowenstein Sandler LLP 23.1 Consent of Lowenstein Sandler LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CINGULATE INC. Dated: August 19, 2024 By: /s/ Shane J. Schaffer Name: Shane J. Schaffer Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR